相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- BostonGene and Kyoto University have announced a research collaboration to develop advanced biological signatures for targeted treatment strategies in esophageal squamous cell carcinoma (ESCC) patients. - The partnership will leverage BostonGene's AI-powered platform to analyze tumor molecular profiles and assess their correlation with response to immune checkpoint inhibitor and chemoradiotherapy combination therapy. - The research builds on the NOBEL Phase II trial led by Dr. Manabu Muto, integrating genomic and transcriptomic profiling to identify immune-related biomarkers for improved patient stratification and clinical trial optimization.
- The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded up to $5 million to Nagasaki University to develop a novel "nanoball" mRNA vaccine platform that encases mRNA in negatively-charged nano-sized particles for enhanced stability and delivery. - The technology will be tested against severe fever with thrombocytopenia syndrome virus (SFTSV), a tick-borne pathogen threatening East Asia, with AI-powered antigen design from NEC OncoImmunity to optimize vaccine targets. - The nanoball platform offers significant advantages including freeze-drying capability, room temperature storage, and potential rapid adaptation to combat future pandemic threats including hypothetical "Disease X." - This innovation could revolutionize vaccine accessibility in low- and middle-income countries by eliminating complex cold-chain requirements while supporting the global 100 Days Mission for pandemic preparedness.
- NEC Corporation and Chugai Pharmaceutical have successfully tested an AI system that can predict effective cancer drug combinations, potentially reducing prediction time by approximately 50% compared to conventional methods. - The graph-based AI technology leverages biochemical information and clinical trial data from AACT and ChEMBL databases to quickly suggest candidate drug combinations that could enhance cancer treatment efficacy. - In experimental validation using approximately 400 cancer drug combinations, the system demonstrated accurate predictions with highly convincing rationales, showing potential to streamline drug discovery processes. - The technology addresses the time-consuming manual research traditionally required for drug combination therapy development, which involves analyzing vast amounts of publications and clinical trial data.
- NEC Bio Therapeutics' NECVAX-NEO1, combined with checkpoint inhibitors, demonstrates encouraging interim results in a Phase 1 trial for solid tumors. - The personalized, bacteria-based oral DNA vaccine induced an ELISPOT response in 68% of neoepitopes, with 40% of patients showing significant neoantigen-specific signals. - After 24 weeks, 80% of patients treated with NECVAX-NEO1 achieved stable disease status, indicating a high disease control rate in melanoma, renal cell, and head and neck cancer patients. - The Phase 1 trial showed no treatment-related toxicities, supporting further investigation of NECVAX-NEO1 as a potential treatment option for difficult-to-treat cancers.
